Routine emergency dept. HIV screenings find only small increase in newly diagnosed HIV patients

July 18, 2010

The use of routine HIV screening in a hospital emergency department, which patients had the option to decline, was associated with only a modest increase in the number of patients with newly diagnosed HIV infection, compared to physician-directed diagnostic rapid HIV testing, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

Jason S. Haukoos, M.D., of the Denver Health Medical Center, Denver, presented the findings of the study at a JAMA media briefing at the International AIDS conference in Vienna.

Infection with the human immunodeficiency virus (HIV) remains an important public health problem in the United States, with more than 1 million people estimated to be infected, and approximately 230,000 infections being undiagnosed. Additionally, approximately 56,000 people are newly infected each year, according to background information in the article. Testing for HIV infection remains an important preventive strategy, and in 2006, the Centers for Disease Control and Prevention (CDC) published revised guidelines for performing HIV testing in health care settings, recommending widespread routine (nontargeted) opt-out (the option to decline) HIV screening in settings where the prevalence of undiagnosed infection was 0.1 percent or greater.

Emergency departments (EDs) have been an important focus for HIV prevention efforts, including testing and screening initiatives, and since 2006, efforts to integrate nontargeted HIV screening into EDs have increased, although limited research supports this practice, and it remains unknown if nontargeted opt-out HIV screening, when incorporated into an ED setting, is associated with the identification of patients with HIV infection as a prevention strategy, the authors write.

Dr. Haukoos and colleagues conducted a study to determine whether nontargeted opt-out rapid HIV screening in a high-volume ED was associated with identification of more patients with newly diagnosed HIV infection than physician-directed diagnostic rapid HIV testing. The study included an urban hospital with an approximate annual ED census of 55,000 patient visits. Patients were 16 years or older and capable of providing consent for rapid HIV testing. The interventions included nontargeted opt-out rapid HIV screening and physician-directed diagnostic rapid HIV testing alternated in sequential 4-month time intervals between April 2007 and April 2009.

Of the 28,043 eligible patients included in the opt-out phase, 6,933 patients (25 percent) completed HIV testing (6,702 patients were screened; 231 patients were diagnostically tested). Of the 6,702 patients screened, 10 patients (0.15 percent) had new HIV diagnoses. Of the remaining 21,281 patients who opted out or were opted out by registration personnel, 231 (1 percent) subsequently underwent diagnostic testing and 5 patients (2.2 percent) had new diagnoses.

Of the 29,925 eligible patients included in the diagnostic phase, 243 patients (0.8 percent) underwent testing and 4 patients (1.6 percent) had new diagnoses. The overall prevalence of newly detected HIV infection during the opt-out phase (including those diagnostically tested) and during the diagnostic phase was 15 in 28,043 (0.05 percent) and 4 in 29,925 (0.01 percent), respectively.

The authors found that nontargeted opt-out screening was associated with newly identified HIV-infected patients. Most of these patients were identified late in the course of disease and met serological criteria for acquired immunodeficiency syndrome (AIDS) at the time of their diagnoses.

"Nontargeted opt-out rapid HIV screening in conjunction with diagnostic testing was associated with approximately 30 times the number of rapid HIV tests performed, yet only a few more patients were newly identified with HIV infection when compared with diagnostic testing alone," the authors write.

(JAMA. 2010;304[3]:284-292. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: HIV Screening in Health Care Settings - Some Progress, Even More Questions

Roland C. Merchant, M.D., M.P.H., Sc.D., and Michael J. Waxman, M.D., of the Warren Alpert Medical School of Brown University, Providence, R.I., write in an accompanying editorial that "the optimal models for HIV screening in health care settings are not yet known and most likely will not be a one-size-fits-all approach."

"Research is needed to determine who should initiate screening, as well as how, and when screening should be conducted during medical care. The current CDC recommendations might not be the optimal methods for all settings, but they offer suggestions from which models can be tailored to a setting's and patients' needs. New tools are available for HIV testing; it is up to clinicians to use them and find those that work best. The next greatest challenge will be to identify which HIV screening models are most effective and efficient and can be self-sustaining after research funding has been removed."
-end-
(JAMA. 2010;304[3]:348-349. Available pre-embargo to the media at www.jamamedia.org)

Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.

The JAMA Network Journals

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.